## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

# STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Robichaud Albert		2. Issuer Name <b>and</b> Ticker or Trading S Sage Therapeutics, Inc. [ S.								(Check	all app	olicable)	g Person(s) to Is 10% C Other	
(Last) (First) (Middle) C/O SAGE THERAPEUTICS, INC. 215 FIRST STREET		3. Date of Earliest Transaction (Month/Day/Year) 12/14/2017								X	below) below)  Chief Scientific Officer			
(Street) CAMBRIDGE MA 02142 (City) (State) (Zip)	4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Indiv Line) X	· '			
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned														
Date	2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) o Disposed Of (D) (Instr. 3, 4 a			d 5)	Beneficially Owned Followi		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
					Code	v	Amount	(A) or (D)	Price			ted action(s) 3 and 4)		(Instr. 4)
ommon Stock 12/14/2017				S <sup>(1)</sup>		1,500	D	\$156	156.31 <sup>(2)</sup>		52,759	D		
Common Stock 12/	12/14/2017				S <sup>(1)</sup>		3,700	D	\$157	7.27 <sup>(3)</sup>		49,059	D	
Common Stock 12/	/14/2017	7		S <sup>(1)</sup>		16,748	D	\$158	58.18(4)		32,311	D		
Common Stock 12/	12/14/2017				S <sup>(1)</sup>		8,734	D	\$159	59.46 <sup>(5)</sup>		23,577	D	
Common Stock 12/	12/14/2017				S <sup>(1)</sup>		21,410	D	\$160	\$160.12 <sup>(6)</sup>		02,167	D	
Common Stock 12/	12/14/2017				S <sup>(1)</sup>		6,187	D	\$163	\$161.4 <sup>(6)</sup>		5,980	D	
Common Stock 12/	12/14/2017		'		S <sup>(1)</sup>		700	D	\$162	.21(7)	95,280		D	
Common Stock 12/	12/14/2017				<b>S</b> <sup>(1)</sup>		1,021	D	\$163	.93(8)	94,259		D	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)														
1. Title of Derivative Security (Instr. 3)  2. Conversion or Exercise Price of Derivative Security  3. Transaction Date Execution Date (Month/Day/Year) if any (Month/Day/Year)	Code (	Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Exerction D		7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)		Deriv Secu (Inst		derivative Securities	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
	Code	v	(A)	(D)	Date Exercis	sable	Expiration Date	;	or Number of Shares					

## **Explanation of Responses:**

- 1. The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- 2. This transaction was executed in multiple trades at prices ranging from \$155.81 USD to \$156.72 USD. The price reported above reflects the weighted average sale price.
- 3. This transaction was executed in multiple trades at prices ranging from \$156.82 USD to \$157.80 USD. The price reported above reflects the weighted average sale price.
- 4. This transaction was executed in multiple trades at prices ranging from \$157.83 USD to \$158.81 USD. The price reported above reflects the weighted average sale price.
- 5. This transaction was executed in multiple trades at prices ranging from \$158.90 USD to \$159.8901 USD. The price reported above reflects the weighted average sale price. 6. This transaction was executed in multiple trades at prices ranging from \$159.90 USD to \$160.89 USD. The price reported above reflects the weighted average sale price.
- 7. This transaction was executed in multiple trades at prices ranging from \$162.01 USD to \$162.45 USD. The price reported above reflects the weighted average sale price.
- 8. This transaction was executed in multiple trades at prices ranging from \$163.57 USD to \$164.24 USD. The price reported above reflects the weighted average sale price.

#### Remarks:

/s/ Anne Marie Cook, as Attorney-in-Fact for Albert Robichaud

12/14/2017

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.